eIF3: Function in Protein Synthesis and Role in Disease

Eukaryotic initiation factor 3, or eIF3, is the largest and most complex protein assembly in the translation initiation machinery, and it touches nearly every step involved in making proteins from messenger RNA. In mammals, it is built from thirteen subunits that together weigh roughly 800 kilodaltons, making it a massive molecular scaffold that organizes other initiation factors on the ribosome. What makes eIF3 especially interesting is that it does far more than help ribosomes find the start of a message. It selectively controls which mRNAs get translated, it participates in termination and recycling, viruses exploit it to hijack cell machinery, and mutations in its subunits are linked to cancer and rare developmental disorders. Understanding eIF3 means understanding a central control point in gene expression.

The Architecture of a Thirteen-Subunit Giant

Mammalian eIF3 is made up of thirteen subunits, labeled eIF3a through eIF3m. Eight of these form a rigid structural core held together by two types of protein domains that eIF3 shares with two other large cellular machines: the proteasome lid and the COP9 signalosome. The remaining five subunits attach more loosely to this core, giving the complex a modular design where peripheral pieces can flex and reach out to contact different partners.¹ Electron microscopy studies have confirmed that the spatial arrangement of these eight core subunits closely mirrors the proteasome lid, suggesting the two complexes descended from a shared ancestor and repurposed the same architectural blueprint for very different jobs.²

Not all organisms need all thirteen subunits. Budding yeast gets by with just five core subunits (a, b, c, i, and g), all of which have counterparts in mammalian eIF3. The seven additional subunits found in mammals (d, e, f, h, k, l, and m) appear to have been added over evolutionary time, expanding the complex’s regulatory repertoire.³ Reconstitution experiments have produced a surprise here: two subunits conserved between yeast and humans, eIF3g and eIF3i, turn out to be dispensable for assembling an active mammalian eIF3 complex. Instead, the functional core in mammals relies on three conserved subunits (eIF3a, eIF3b, eIF3c) plus three that are absent in yeast (eIF3e, eIF3f, eIF3h).⁴ Early cloning work comparing human and yeast eIF3 subunit sequences found unexpectedly large structural differences, underscoring that the complex has diversified substantially across the tree of life even while retaining its central role in protein synthesis.⁵

How eIF3 Orchestrates Translation Initiation

The textbook job of eIF3 is to serve as a scaffold that brings other initiation factors together on the small (40S) ribosomal subunit and coordinates their actions during the earliest steps of protein synthesis.⁶ It mediates formation of the 43S pre-initiation complex, helps recruit capped mRNA, and supports the scanning process in which the ribosome moves along the message searching for the correct start codon.⁷

Individual subunits play distinct roles in this process. The eIF3b subunit, for example, makes direct contacts with eIF1 (a factor critical for accurate start-codon selection), with the small ribosomal RNA, and with eIF2, the factor that delivers the initiator transfer RNA. These interactions place eIF3b at the heart of the scanning machinery, where it helps ensure that translation begins at the right spot.⁸ Meanwhile, the eIF3d subunit is critical for getting the whole complex onto the ribosome in the first place. When eIF3d is knocked down, the amount of eIF3 associated with pre-initiation complexes drops to roughly a third of normal levels, and free 40S subunits accumulate because they can no longer be efficiently loaded with initiation factors.⁹

eIF3 also works with eIF4F, the cap-binding complex, to thread mRNA into the ribosome’s entry channel. In vitro reconstitution work supports a model in which eIF4E (the cap-recognition protein), eIF4G (a large scaffolding protein), and eIF3 together position eIF4E at the leading edge of the 40S subunit so that the mRNA can be inspected from its very first nucleotide.¹⁰

eIF3 Does Not Leave After Initiation

For years, the assumption was that eIF3 falls off the ribosome once translation begins. That picture has changed. Several lines of evidence now show that eIF3 can remain associated with ribosomes during elongation, termination, and recycling, performing distinct jobs at each stage.

During termination, eIF3 promotes the initial binding of eukaryotic release factor eRF1 to the stop codon and may facilitate the subsequent step in which eRF3 hydrolyzes GTP. Because eIF3 can stimulate eRF1 even when eRF3 is absent, its main contribution appears to be in the very first step of translation termination.¹¹ In yeast, mutations in core eIF3 subunits reduce stop-codon read-through, meaning the ribosome becomes better at recognizing stop signals. The effects on initiation and termination are genetically separable, confirming that eIF3’s termination role is not just a byproduct of its initiation function.¹²

Reinitiation is another post-initiation job. Many mRNAs contain short upstream open reading frames (uORFs) in their leader regions. After the ribosome translates one of these small uORFs, it normally needs to resume scanning and reinitiate at the main coding sequence downstream. The eIF3h subunit is essential for this. Mutations in eIF3h cause ribosomes to permanently lose their reinitiation competence at a faster rate, meaning fewer of them ever reach the main start codon.¹³

Selective mRNA Translation and Stress Responses

Perhaps the most exciting recent development is the realization that eIF3 does not treat all mRNAs equally. It recognizes specific RNA structures in the untranslated leader regions of certain messages and uses those contacts to drive their translation through nonstandard routes.

One well-studied example involves the oncogene c-Jun. eIF3 binds a structured RNA element in the c-Jun 5′ untranslated region, and this interaction drives ribosome recruitment in a manner that resembles internal ribosome entry but still requires recognition of the mRNA cap.¹⁴ In a separate pathway, a single methyl modification on adenosine (m6A) in the 5′ leader can directly bind eIF3, which then recruits the 43S complex to initiate translation without requiring eIF4E, the standard cap-binding protein. This gives cells a way to make certain proteins even when cap-dependent translation is shut down.¹⁵

Beyond initiation, eIF3 binding sites in 5′ UTRs can keep eIF3 tethered to the ribosome during the synthesis of certain endoplasmic reticulum membrane proteins. When those binding sites are disrupted, the newly synthesized proteins misfold and accumulate in abnormal membrane structures. The mechanism involves eIF3 recruiting specific chaperones to the ribosome during early elongation, essentially making sure the protein folds correctly as it emerges.¹⁶ This is a striking finding because it means genetic instructions encoded in untranslated RNA can direct protein quality control during synthesis.

eIF3 also acts as a metabolic sensor. When cells face nutrient starvation, a sugar modification (O-GlcNAc) on eIF3a is removed, which promotes eIF3 retention on elongating ribosomes and drives reinitiation of ATF4, a master transcription factor for the stress response. Eliminating the modification site via gene editing turns on ATF4 even when nutrients are plentiful.¹⁷ In a related mechanism, the cap-binding activity of eIF3d is activated during metabolic stress through reduced phosphorylation near its cap-binding pocket. Once activated, eIF3d controls a gene program enriched in factors important for glucose balance, including members of the mTOR pathway. This eIF3d-directed translation reprogramming is essential for cell survival during prolonged glucose deprivation.¹⁸

How Viruses Exploit eIF3

Because eIF3 sits at the crossroads of ribosome recruitment, it is a prime target for viral manipulation. Hepatitis C virus (HCV) provides the best-studied example. The HCV genome contains an internal ribosome entry site (IRES) that directly binds eIF3 and uses that interaction to initiate translation of viral proteins without needing a cap structure. Several other RNA viruses employ structurally similar elements.¹⁹

SARS-CoV-2 takes a different approach. Its non-structural protein 1 (Nsp1) blocks host mRNA from entering the ribosome by plugging the mRNA entry channel, effectively shutting down the cell’s own protein production. Crosslinking studies have revealed that the N-terminal region and linker of Nsp1 contact the eIF3g subunit, and Nsp1 preferentially associates with 40S-43S complexes, meaning it targets ribosomes that are in the process of initiating translation. This interaction may help Nsp1 find and destroy host mRNAs while sparing viral ones.²⁰

eIF3 Subunits in Cancer

Given that eIF3 controls which proteins cells make and how quickly, it is not surprising that abnormalities in its subunits show up in many cancers. The connections go beyond simple overexpression.

The eIF3a subunit affects how cancer patients respond to chemotherapy. In lung cancer, higher eIF3a expression is associated with better responses to platinum-based drugs, and laboratory experiments show that eIF3a levels inversely control DNA repair activity: knocking eIF3a down increases repair and drug resistance, while overexpressing it decreases both.²¹ A similar relationship holds in breast cancer, where eIF3a enhances sensitivity to anthracycline drugs by suppressing the translation of specific DNA double-strand break repair proteins. Breast cancer patients with high eIF3a or low expression of these repair factors had better outcomes on anthracycline-based regimens.²²

The eIF3e subunit has its own cancer story. In endometrial cancer, a ubiquitin ligase called TRIM35 marks eIF3e for destruction, which in turn suppresses a signaling pathway that drives malignant proliferation. When TRIM35 is lost, eIF3e accumulates and tumor growth accelerates.²³ On the metabolic side, cells lacking eIF3e show a roughly 60% drop in mitochondrial oxygen consumption, and loss of eIF3d or eIF3h produces similar reductions. This is because these subunits are needed to translate certain mitochondrial electron transport chain components, and their absence leads to global reductions of about 25% in protein synthesis along with increased sensitivity to stress.²⁴

Developmental Disorders Tied to eIF3 Mutations

If subtle shifts in eIF3 subunit levels can alter cancer behavior, it makes sense that severe loss-of-function mutations would cause developmental problems. Recent human genetics studies are confirming this.

Four unrelated individuals carrying homozygous variants in the EIF3K gene were found to share a syndrome of global developmental delay, microcephaly, proportionate short stature, distinctive craniofacial features, digit flexion deformities, and a congenital heart defect called patent ductus arteriosus. Functional experiments support the conclusion that these biallelic EIF3K variants cause an autosomal recessive neurodevelopmental disorder.²⁵

A broader picture is emerging from studies of EIF3A and EIF3B. Loss-of-function variants in these genes produce a syndrome that spans the cardiovascular, craniofacial, and neurodevelopmental systems. Among affected individuals, developmental delay, speech and language delay, intellectual disability, and learning difficulties are common. Behavioral features including attention-deficit hyperactivity disorder and autism spectrum traits have been reported. Facial differences, particularly around the eye region, overlap with features seen in individuals carrying larger chromosomal deletions in the same region.²⁶ These findings make clear that eIF3 is not simply a housekeeping factor for generic protein synthesis. The clinical presentations vary depending on which subunit is affected, pointing to specialized roles for individual subunits during development.

Moonlighting Outside the Ribosome

eIF3 subunits have been found in places you would not expect a translation factor: the cell nucleus. The eIF3f subunit, for instance, physically associates with hundreds of nuclear proteins, including transcription factors such as STAT3. When eIF3f is overexpressed in lung cancer cells, it promotes invasion, and that invasive behavior depends on STAT3 signaling. Inhibiting STAT3 with a small molecule blocks the effect.²⁷

The eIF3k subunit has been found at PML nuclear bodies, structures involved in tumor suppression and antiviral defense. eIF3k directly interacts with the PML protein, and alternative splicing of both PML and eIF3k may regulate whether eIF3k localizes there.²⁸ What these nuclear functions accomplish at a physiological level is still being worked out, but their existence challenges the assumption that translation factors belong exclusively in the cytoplasm.

eIF3 also physically links translation to protein degradation. In yeast, eIF3 associates with proteasomes and translation machinery in a supercomplex dubbed the “translasome.” This arrangement may allow misfolded proteins to be destroyed as soon as they emerge from the ribosome, preventing toxic accumulation.²⁹

Targeting eIF3 with Drugs

The fact that eIF3 subunits are deregulated in many cancers and control stress-response programs makes them attractive drug targets. Work in this area is still early stage, but progress is being made on multiple fronts.

The eIF3a subunit has been flagged as a potential anticancer target, and small-molecule inhibitors are under development.³⁰ More recently, researchers have developed first-in-class compounds that target the eIF3e subunit. These compounds inhibit the translational response to low oxygen (hypoxia), a condition that tumors routinely exploit to become more invasive. In cell-based assays, the inhibitors reduce invasion in response to hypoxia, and one compound has already been shown to inhibit metastasis in an animal model.³¹ Complementary work has confirmed that eIF3d and eIF3e mediate selective translation of hypoxia-response genes and identified small molecules that specifically target eIF3e to reduce this stress-induced translation program.³²

The therapeutic logic is appealing: rather than trying to block all protein synthesis (which would kill healthy cells), these approaches aim to disrupt the selective translation programs that tumor cells depend on for survival under stress. Whether that selectivity will hold up in clinical settings remains to be seen, but the specificity of individual eIF3 subunits for particular mRNA sets offers a starting point that most other translation factors do not.

eIF3 and the Proteasome Connection

The structural resemblance between eIF3 and the proteasome lid is more than a curiosity. Both complexes share the same types of protein-protein interaction domains, and their core subunits occupy similar spatial positions. The proteasome destroys proteins; eIF3 helps build them. That two machines with opposite functions share architectural ancestry raises questions about how both complexes evolved and whether the shared scaffold enables direct physical communication between translation and degradation. The translasome discovery mentioned above suggests it does: by associating with both ribosomes and proteasomes, eIF3 may physically couple the birth of a protein to the machinery that decides whether it lives or dies. Estimates from earlier work suggest that somewhere between a third and half of newly made proteins are destroyed shortly after synthesis, many co-translationally, and this spatial linkage could help make that quality-control process efficient.²⁹

From a disease standpoint, this coupling is relevant because many neurodegenerative conditions involve the accumulation of misfolded proteins. If eIF3-mediated quality control at the ribosome breaks down, the consequences could extend well beyond the translational defects you might initially expect. The intersection of translation, folding, and degradation is an area where eIF3 research is likely to expand considerably in the coming years.